Leukemia, particularly acute myeloid leukemia (AML), is one of the deadliest forms of cancer. Less than one in five adult patients survives 10 years after diagnosis.

With treatment options that have remained largely unchanged for over three decades, those that do survive the disease face long-term side effects from toxic therapies, which may diminish their lifespan and quality of life. This must change.


Leukemia research is on the verge of a major paradigm shift and future success will require innovative, thoughtful leaders and increased collaboration between scientists, clinicians and teams of health care professionals.

Fuelled by a revolution in next generation sequencing, remarkable advances in stem cell biology and methods for disease modelling, our understanding of how leukemia develops has expanded tremendously over the past decade. With this new knowledge comes an unprecedented opportunity to identify and develop more effective targeted drugs or immune-based treatments that will improve the standard of care.

Right now, BC Cancer has a unique opportunity to revolutionize leukemia treatment in British Columbia and champion research into new therapies with two critical projects.

PROJECT I: Uncovering New, More Effective Treatments for Leukemia
  • Led by Dr. Florian Kuchenbauer’s expertise, BC Cancer aims to act quickly on discoveries emerging from BC Cancer’s Terry Fox Laboratory and apply them directly to patients in the Leukemia/Bone Marrow Transplant (L/BMT) Program of B.C.
PROJECT II: CAR-T Immunotherapy Clinical Trials for Leukemia    
  • Chimeric Antigen Receptor T (CAR-T) cells are a powerful new tool for treating leukemia. BC Cancer is the lead institution for a new national CAR-T development program that will develop the infrastructure, tools and materials to launch CAR-T cell clinical trials this year, with the end goal of making CAR-T therapy available as standard of care for leukemia patients in B.C

Kristin's Story - Living with Chronic Myeloid Leukemia (CML)

You can support blood cancer research


To learn more or to support Blood Cancer research, contact:

Elissa Morrisette
Executive Director, Development 
PH: 604.707.5992